Abstract
Background: A long-acting somatostatin analogue (lanreotide) is used in the management of a diazoxide-unresponsive diffuse form of congenital hyperinsulinism (CHI). However, no reports of its use in patients with the focal form of CHI exist. Case 1: A 1-month-old boy diagnosed with diazoxide-unresponsive CHI due to a paternal heterozygous ABCC8 gene mutation showed partial response to octreotide. 18F-DOPA-PET/CT scan revealed a focal lesion in the pancreatic head. Surgical removal of the lesion was unsuccessful. He was switched to monthly lanreotide treatment at the age of 11 months, which stabilised his blood glucose over a 12-month period. Case 2: A 1-month-old boy with diazoxide-unresponsive CHI due to a paternal heterozygous KCNJ11 gene mutation was partially responsive to octreotide. 18F-DOPA-PET/CT scan confirmed a focal pancreatic head lesion. Over 6 months, he underwent 3 lesionectomies and afterwards responded to octreotide. At the age of 9 months, treatment was switched to monthly lanreotide. Currently, he is aged 3, with stable glycaemia, and improved fasting tolerance. Case 3: A 3-week-old girl with a paternal heterozygous ABCC8 gene mutation was unresponsive to diazoxide. 18F-DOPA-PET/CT scan confirmed a focal pancreatic head lesion. She responded to octreotide, and her parents preferred to avoid pancreatic surgery. At the age of 20 months, treatment was switched to monthly lanreotide, resulting in euglycaemia over the last 7 months. Conclusion: CHI patients with focal pancreatic head lesions are challenging, especially if not surgically amenable. Conservative treatment is preferable, and lanreotide might be an option. The therapeutic impact of lanreotide treatment in patients with the focal forms of CHI should be confirmed in prospective studies with close monitoring of the side effects.
References
1.
Senniappan
S
, Shanti
B
, James
C
, Hussain
K
. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management
. J Inherit Metab Dis
. 2012
Jul
;35
(4
):589
–601
.
[PubMed]
0141-89552.
Kapoor
RR
, Flanagan
SE
, James
C
, Shield
J
, Ellard
S
, Hussain
K
. Hyperinsulinaemic hypoglycaemia
. Arch Dis Child
. 2009
Jun
;94
(6
):450
–7
.
[PubMed]
0003-98883.
Shah
P
, Rahman
AS
, Demirbilek
H
, Güemes
M
, Hussain
K
. Hyperinsulinaemic hypoglycaemia in children and adults
. Lancet Diabetes Endocrinol
. 2016
;•••
:
[PubMed]
2213-85874.
Charles
A
, Stanley
AC
. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders J Clin Endocrinol Metab
. 2016
Mar
;101
(3
):815
–26
.
[PubMed]
5.
Cabezas
OR
, Flanagan
SE
, Stanescu
H
, García-Martínez
E
, Caswell
R
, Lango-Allen
H
, Antón-Gamero
M
, Argente
J
, Bussell
AM
, Brandli
A
, Cheshire
C
, Crowne
E
, Dumitriu
S
, Drynda
R
, Hamilton-Shield
JP
, Hayes
W
, Hofherr
A
, Iancu
D
, Issler
N
, Jefferies
C
, Jones
P
, Johnson
M
, Kesselheim
A
, Klootwijk
E
, Koettgen
M
, Lewis
W
, Martos
JM
, Mozere
M
, Norman
J
, Patel
V
, Parrish
A
, Pérez-Cerdá
C
, Pozo
J
, Rahman
SA
, Sebire
N
, Tekman
M
, Turnpenny
PD
, Hoff
WV
, Viering
DHHM
, Weedon
MN
, Wilson
P
, Guay-Woodford
L
, Kleta
R
, Hussain
K
, Ellard
S
, Bockenhauer
D
.: Polycystic Kidney Disease with Hyperinsulinemic Hypoglycemia Caused by a Promoter Mutation in Phosphomannomutase 2 JASN ASN.2016
;12 : 13126.
Damaj
L
, le Lorch
M
, Verkarre
V
, Werl
C
, Hubert
L
, Nihoul-Fékété
C
, et al. Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism
. J Clin Endocrinol Metab
. 2008
Dec
;93
(12
):4941
–7
.
[PubMed]
0021-972X7.
Verkarre
V
, Fournet
JC
, de Lonlay
P
, Gross-Morand
MS
, Devillers
M
, Rahier
J
, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia
. J Clin Invest
. 1998
Oct
;102
(7
):1286
–91
.
[PubMed]
0021-97388.
Arya
VB
, Güemes
M
, Nessa
A
, Alam
S
, Shah
P
, Gilbert
C
, et al. Clinical and histological heterogeneity of congenital hyperinsulinism due to paternally inherited heterozygous ABCC8/KCNJ11 mutations
. Eur J Endocrinol
. 2014
Dec
;171
(6
):685
–95
.
[PubMed]
0804-46439.
Hardy
OT
, Hernandez-Pampaloni
M
, Saffer
JR
, Scheuermann
JS
, Ernst
LM
, Freifelder
R
, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism
. J Clin Endocrinol Metab
. 2007
Dec
;92
(12
):4706
–11
.
[PubMed]
0021-972X10.
Maiorana
A
, Barbetti
F
, Boiani
A
, Rufini
V
, Pizzoferro
M
, Francalanci
P
, et al. Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening
. Clin Endocrinol (Oxf)
. 2014
Nov
;81
(5
):679
–88
.
[PubMed]
0300-066411.
de Lonlay-Debeney
P
, Poggi-Travert
F
, Fournet
JC
, Sempoux
C
, Dionisi Vici
C
, Brunelle
F
, et al. Clinical features of 52 neonates with hyperinsulinism
. N Engl J Med
. 1999
Apr
;340
(15
):1169
–75
.
[PubMed]
0028-479312.
Leibowitz
G
, Glaser
B
, Higazi
AA
, Salameh
M
, Cerasi
E
, Landau
H
. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up
. J Clin Endocrinol Metab
. 1995
Feb
;80
(2
):386
–92
.
[PubMed]
0021-972X13.
Rens-Domiano
S
, Reisine
T
. Biochemical and functional properties of somatostatin receptors
. J Neurochem
. 1992
Jun
;58
(6
):1987
–96
.
[PubMed]
0022-304214.
Kvols
LK
, Woltering
EA
. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors
. Anticancer Drugs
. 2006
Jul
;17
(6
):601
–8
.
[PubMed]
0959-497315.
Susini
C
, Buscail
L
. Rationale for the use of somatostatin analogs as antitumor agents
. Ann Oncol
. 2006
Dec
;17
(12
):1733
–42
.
[PubMed]
0923-753416.
Murray
RD
, Melmed
S
. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
. J Clin Endocrinol Metab
. 2008
Aug
;93
(8
):2957
–68
.
[PubMed]
0021-972X17.
Heron
I
, Thomas
F
, Dero
M
, Gancel
A
, Ruiz
JM
, Schatz
B
, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly
. J Clin Endocrinol Metab
. 1993
Mar
;76
(3
):721
–7
.
[PubMed]
0021-972X18.
Caron
P
, Beckers
A
, Cullen
DR
, Goth
MI
, Gutt
B
, Laurberg
P
, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly
. J Clin Endocrinol Metab
. 2002
Jan
;87
(1
):99
–104
.
[PubMed]
0021-972X19.
Modan-Moses
D
, Koren
I
, Mazor-Aronovitch
K
, Pinhas-Hamiel
O
, Landau
H
. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel)
. J Clin Endocrinol Metab
. 2011
Aug
;96
(8
):2312
–7
.
[PubMed]
0021-972X20.
Kühnen
P
, Marquard
J
, Ernert
A
, Meissner
T
, Raile
K
, Wannenmacher
G
, et al. Long-term lanreotide treatment in six patients with congenital hyperinsulinism
. Horm Res Paediatr
. 2012
;78
(2
):106
–12
.
[PubMed]
1663-281821.
Le Quan Sang
KH
, Arnoux
JB
, Mamoune
A
, Saint-Martin
C
, Bellanné-Chantelot
C
, Valayannopoulos
V
, et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide
. Eur J Endocrinol
. 2012
Feb
;166
(2
):333
–9
.
[PubMed]
0804-464322.
Shah
P
, Rahman
SA
, McElroy
S
, Gilbert
C
, Morgan
K
, Hinchey
L
, Senniappan
S
, Levy
H
, Amin
R
, Hussain
K
: Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact Horm Res Paediatr 2015
; 84(5):355–60.23.
van der Steen
I
, van Albada
ME
, Mohnike
K
, Christesen
HT
, Empting
S
, Salomon-Estebanez
M
, et al. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism
. Horm Res Paediatr
. 2018
;89
(2
):82
–9
.
[PubMed]
1663-281824.
Welters
A
, Lerch
C
, Kummer
S
, Marquard
J
, Salgin
B
, Mayatepek
E
, et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers
. Orphanet J Rare Dis
. 2015
Nov
;10
(1
):150
.
[PubMed]
1750-1172© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
